Dvorak B.F. et al. Beta-(1,3/1,6)-D-glucan from Pleurotus ostreatus in the prevention of recurrent respiratory tract infections: An international multicentric clinical study. Front Pediatr. 2022;10:1009878.
Why this study
Oyster β-glucans are among the most-studied "immune" components of mushrooms. Pleuran (β-(1,3/1,6)-glucan) is sold as a supplement for children with frequent colds. This is the first large international study on a real population.
Methods
- 1030 children (mean age 3.5) from 7 countries with recurrent RTIs.
- 3 months of pleuran + 3 months of follow-up; comparison with the same period of the previous year (October–March).
- Endpoints: number and duration of RTIs by type (upper/lower).
Findings
- RTI count fell from 7.07 to 3.87 episodes per half-year (−45%, p<0.001).
- Reductions across all RTI subtypes, including duration.
- Safety profile confirmed — no serious AEs recorded.
Limitations — important
- Before/after design with no placebo or randomization: comparing with one's own previous year is sensitive to seasonality (mild/severe epidemic year), the child's maturing immunity and the "being observed" effect.
- Manufacturer-sponsored work — take into account.
Why it matters
Pleuran is a rare mushroom product with paediatric data and a large sample. But the card is a teaching example that "large n ≠ randomized design": the effect may be real (it fits β-glucan mechanism), but the evidential strength is below an RCT.